A Peek Into The Market Before The Trading Starts - Akamai Techs (NASDAQ:AKAM), Cleveland-Cliffs (NYSE:CLF)

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Pre-open moversUS stock futures are higher this morning, as investors are awaiting the ISM index. Futures for the Dow Jones Industrial Average surged 28 points to 14,144.00 and S&P 500 index futures rose 3 points to 1,528.70. Nasdaq 100 futures climbed 7.50 points to 2,767.50.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

A Peek Into Global Markets European markets were higher today. The STOXX Europe 600 Index surged 1.20%, London's FTSE 100 Index gained 0.72%, French CAC 40 Index rose 1.13% and German DAX 30 index surged 1.56%.Asian markets ended higher, with Japan's Nikkei Stock Average gaining 0.27%, China's Shanghai Composite surging 2.33% and Australia's S&P/ASX 200 rising 1.19%. Hong Kong's Hang Seng Index gained 0.10% and India's Sensex climbed 1.40%.Broker Recommendation

Analysts at BMO Capital downgraded Cliffs Natural Resources (NYSE: CLF) from “outperform” to “market perform.” The target price for Cliffs Natural has been lowered from $50 to $27. Cliffs Natural shares rose 0.08% to $23.80 in after-hours trading. Breaking news

MarketAxess Holdings (NASDAQ: MKTX) has completed its previously announced acquisition of Xtrakter Limited, a leading provider of regulatory transaction reporting, financial market data and trade matching services to the European securities markets. To read the full news, click here.
From the International Hotel Investment Forum (IHIF) in Berlin, Starwood Hotels & Resorts Worldwide (NYSE: HOT) today announced plans to open 50 new hotels in Europe over the next five years, increasing its European hotel portfolio by 30%. To read the full news, click here.
Akamai Technologies (NASDAQ: AKAM) announced today that eLynx Technologies is using Akamai Terra Enterprise Solutions to provide performance optimization for the company's SCADALynx™ technology. To read the full news, click here.
Oncolytics Biotech (NASDAQ: ONCY) today announced that it has completed patient enrollment in a Phase 2 clinical trial evaluating intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours (REO 016). To read the full news, click here.